Injection-site pain (ISP) is a commonly reported subjective side effect with the subcutaneous (SC) administration of biological agents, yet it may only be a concern to some.

Multiple factors, including those related to product formulation (e.g. pH, volume, excipients, injection process) and to the patient (low body weight, gender and age) have the potential to contribute to ISP.

While total elimination of ISP remains unlikely, it can be minimised by helping the patient develop a competent injection technique and by lowering their treatment-related anxieties.

Other interventions to help minimise ISP include psychological interventions, allowing biologics to reach room temperature prior to injection, using the injection device most suitable for the individual patient and selecting an alternative drug formulation, when available.

Productive patient–physician communication remains important in order to support and optimise treatment experience and adherence, while also providing the opportunity for patients to discuss any ISP-related issues.